Japan PPI inflation slips to 11-mth low in July
WEXFORD, Pa. - Coeptis, Inc. (NASDAQ:COEP), a $25.3 million market cap biotechnology company whose stock has surged over 200% in the past six months, has announced the creation of COEP Venture Group, an investment arm focused on funding and accelerating startups in the fields of Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents. The initiative is designed to support emerging companies that are at the cutting edge of automation and intelligent system technologies. According to InvestingPro data, the company’s stock has shown significant momentum, with a 124% return year-to-date.
With the goal of enhancing business efficiency and decision-making, COEP Venture Group will provide capital, strategic mentorship, and access to industry networks to high-potential startups. Dave Mehalick, CEO of Coeptis Therapeutics Holdings Inc., emphasized the company’s commitment to investing in disruptive technologies that have the potential to redefine industries. InvestingPro analysis reveals that while the company operates with moderate debt levels, its current ratio of 0.4 suggests careful cash management will be crucial for these new ventures.
The venture group will also utilize NexGenAI Solutions Group, part of Coeptis’s recent acquisition, NexGenAI Affiliates Group, to offer marketing services to its portfolio companies, ensuring they receive strategic exposure and market positioning to scale rapidly.
Michael Woloshin, a seasoned entrepreneur with expertise in technology, AI, and marketing automation, will lead COEP Venture Group. His previous experience includes co-founding Recruiter.com and founding NexGenAI Solutions Group. Woloshin’s leadership is expected to drive the group’s mission to foster innovation and expand market opportunities for technology companies.
COEP Venture Group’s investment focus will include AI, RPA, AI Agents, and other emerging technologies such as blockchain applications, data analytics platforms, and next-generation enterprise software.
Coeptis, Inc. and its subsidiaries, including Coeptis Pharmaceuticals, GEAR Therapeutics, SNAP Biosciences, and Coeptis Technologies, operate in the biopharmaceutical and technology sectors. The company’s biopharmaceutical divisions are developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts.
The press release contains forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated. These statements are based on the company’s current expectations and speak only as of the date of their publication. Coeptis has cautioned not to place undue reliance on these forward-looking statements. InvestingPro subscribers have access to 11 additional key insights about COEP, including detailed analysis of its financial health, profitability metrics, and growth potential. Get the full picture with an InvestingPro subscription to make more informed investment decisions.
This article is based on a press release statement from Coeptis Therapeutics.
In other recent news, Coeptis Therapeutics Holdings, Inc. has been making significant strides in its operations. The company recently reported robust earnings and revenue results, securing five new clients for its NexGenAI Affiliates Network platform, valued at $1.25 million, with an expected $450,000 in recurring monthly revenue. This development underscores the initial success of the company’s AI-driven marketing solutions in the biopharma industry.
Coeptis has also made headway in financing through a material definitive agreement with YA II PN, LTD, securing a convertible promissory note of $1.1 million. This comes on the heels of the closing of its Series A Preferred Stock issuance, which raised approximately $10 million.
The company has also announced a significant rebranding to COEPTIS, indicating a strategic shift to include technology and artificial intelligence (AI) in its biopharmaceutical endeavors. This includes the creation of a new Technology Division and the acquisition of the NexGenAI Affiliates Network platform, an AI-powered marketing solution.
In addition to these developments, Coeptis has announced a 1-for-20 reverse stock split of its common stock, following approval from the company’s board of directors and majority stockholders. Lastly, the company completed its acquisition of the NexGenAI Affiliates Network platform and launched a new division, Coeptis Technologies, aimed at diversifying the company’s growth potential in the biotech and pharmaceutical sectors. These are recent developments, and further updates will be provided as they occur.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.